Study identifier:D4194R00005
ClinicalTrials.gov identifier:NCT03798535
EudraCT identifier:N/A
CTIS identifier:N/A
First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
NSCLC
N/A
No
-
All
1156
Observational
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: -
Verified 01 Apr 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
- |